学科主题临床医学
Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: A phase II trial
Li, Jin-luan; Ji, Jia-fu2; Cai, Yong1; Li, Xiao-fan; Li, Yong-heng; Wu, Hao; Xu, Bo; Dou, Fang-yuan3; Li, Zi-yu2; Bu, Zhao-de2; Wu, Ai-wen2; Tham, Ivan W. K.4
关键词Intensity-modulated radiotherapy Capecitabine Rectal cancer
刊名RADIOTHERAPY AND ONCOLOGY
2012
DOI10.1016/j.radonc.2011.07.030
102期:1页:4-9
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Radiology, Nuclear Medicine & Medical Imaging
研究领域[WOS]Oncology ; Radiology, Nuclear Medicine & Medical Imaging
关键词[WOS]TOTAL MESORECTAL EXCISION ; RADIATION-THERAPY ; SMALL-BOWEL ; CHEMORADIOTHERAPY ; SURVIVAL ; VOLUME ; RADIOCHEMOTHERAPY ; LYMPHADENECTOMY ; CHEMOTHERAPY ; NETHERLANDS
英文摘要

Purpose: We aimed to assess the safety and efficacy of preoperative intensity-modulated radiotherapy (IMRT) with oral capecitabine in patients with locally advanced mid-low rectal cancer using a concomitant boost technique.

Materials and methods: Patients with resectable locally advanced mid-low rectal cancer (node-negative >= T3 or any node-positive tumor) were eligible. The eligible patients received IMRT to 2 dose levels simultaneously (50.6 and 41.8 Gy in 22 fractions) with concurrent capecitabine 825 mg/m(2) twice daily 5 days/week. The primary end point included toxicity, postoperative complication, and pathological complete response rate (ypCR). The secondary endpoints included local recurrence rate, progression-free survival (PFS), and overall survival (OS).

Results: Sixty-three eligible patients were enrolled; five patients did not undergo surgery. Of the 58 patients evaluable for pathologic response, the ypCR rate was 31.0%(95% CI 19.1-42.9). Grade 3 toxicities included diarrhea (9.5%), radiation dermatitis (3.2%), and neutropenia (1.6%). There was no Grade 4 toxicity reported. Four (6.9%) patients developed postoperative complications. Two-year local recurrence rate, PFS, and OS were 5.7%, 90.5%, and 96.0%, respectively.

Conclusions: The design of preoperative concurrent boost IMRT with oral capecitabine could achieve high rate of ypCR with an acceptable toxicity profile. (C) 2011 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 102 (2012) 4-9

语种英语
WOS记录号WOS:000300654700002
资助机构Beijing Cancer Hospital
引用统计
被引频次:28[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66037
专题北京大学临床肿瘤学院_胃肠肿瘤中心一病区
北京大学临床肿瘤学院_肿瘤放疗科
作者单位1.Peking Univ, Dept Radiat Oncol, Sch Oncol, Canc Hosp,Beijing Canc Hosp & Inst, Beijing 100142, Peoples R China
2.Beijing Canc Hosp & Inst, Dept Surg Gastroenterol, Beijing, Peoples R China
3.Natl Univ Canc Inst, Dept Radiat Oncol, Singapore, Singapore
4.Beijing Canc Hosp & Inst, Dept Pathol, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Li, Jin-luan,Ji, Jia-fu,Cai, Yong,et al. Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: A phase II trial[J]. RADIOTHERAPY AND ONCOLOGY,2012,102(1):4-9.
APA Li, Jin-luan.,Ji, Jia-fu.,Cai, Yong.,Li, Xiao-fan.,Li, Yong-heng.,...&Tham, Ivan W. K..(2012).Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: A phase II trial.RADIOTHERAPY AND ONCOLOGY,102(1),4-9.
MLA Li, Jin-luan,et al."Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: A phase II trial".RADIOTHERAPY AND ONCOLOGY 102.1(2012):4-9.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Li, Jin-luan]的文章
[Ji, Jia-fu]的文章
[Cai, Yong]的文章
百度学术
百度学术中相似的文章
[Li, Jin-luan]的文章
[Ji, Jia-fu]的文章
[Cai, Yong]的文章
必应学术
必应学术中相似的文章
[Li, Jin-luan]的文章
[Ji, Jia-fu]的文章
[Cai, Yong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。